Jansen Pharmaceuticals has requested that we let our blog readers know about an upcoming educational webinar they are sponsoring on Tuesday, 9/18/18, 7 p.m. ET. The webinar will be discussing their newly approved treatment, apalutamide (Erleada) which is approved by the FDA for men with castrate resistant, non-metastatic prostate cancer, sometimes referred to as M0 (M-zero) disease.
The webinar will be hosted by Dr. David Crawford.
If you are interested in listening to the webinar you can dial in at: 833-877-2773 or you can use your computer by going to: http:://guidancemarkhealthy.abodeconnect.com/janssen/ The conference code is 4198405